# A Systematic Review on Artificial Liver for Implantation

**Authors:** Thi Huong Le, Kinam Hyun, Nima Tabatabaei Rezaei, Chanh Trung Nguyen, Sandra Jessica Hlabano, Van Phu Le, Keekyoung Kim, Kyo-in Koo

PMC · DOI: 10.3390/jfb17020073 · 2026-02-02

## TL;DR

This paper reviews recent progress in implantable artificial livers, highlighting advances in cell sources and scaffolds, while identifying key engineering challenges for clinical translation.

## Contribution

A systematic evaluation of current implantable artificial liver technologies and identification of critical gaps in scaling and functional complexity.

## Key findings

- Significant progress in stem-cell-derived hepatocytes and decellularized extracellular matrix scaffolds.
- Current prototypes remain limited to sub-centimeter sizes, requiring scaling to clinically relevant volumes.
- Key challenges include vascular network integration and functional biliary systems to prevent injury.

## Abstract

Chronic liver disease remains a leading cause of global mortality, yet organ shortages and transplant complications limit the efficacy of orthotopic liver transplantation. While extracorporeal support systems serve as temporary bridges, they fail to restore long-term patient autonomy or replicate complex biosynthetic functions. This systematic review, conducted in accordance with PRISMA 2020 guidelines, evaluates recent advancements in implantable artificial livers (IALs) designed for permanent functional integration. We analyzed 71 eligible studies, assessing cellular sources, fabrication strategies, maturation processes, and functional readiness. Our findings indicate significant progress in stem-cell-derived hepatocytes and bioactive scaffolds, such as decellularized extracellular matrix (dECM). However, a critical technological gap remains in scaling current sub-centimeter prototypes toward clinically relevant volumes (~200 mL). Key engineering challenges include integrating hierarchical vascular networks, requiring primary vessels exceeding 2 mm in diameter for surgical anastomosis, and functional biliary systems to prevent cholestatic injury. Furthermore, while micro-vascularization and protein synthesis are well documented, higher-order functions such as spatial zonation and coordinated metabolic stability remain underreported. Future clinical translation necessitates advancements in multi-cellular patterning, microfluidic-driven maturation, and autologous reprogramming. This review provides a comprehensive roadmap for bridging the gap between biofabricated constructs and organ-scale hepatic replacement, emphasizing the need for standardized functional benchmarks to ensure long-term success.

## Full-text entities

- **Genes:** HNF1B (HNF1 homeobox B) [NCBI Gene 6928] {aka ADTKD3, FJHN, HNF-1-beta, HNF-1B, HNF1beta, HNF2}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Cd34 (CD34 antigen) [NCBI Gene 12490], NID1 (nidogen 1) [NCBI Gene 4811] {aka NID}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, Fah (fumarylacetoacetate hydrolase) [NCBI Gene 14085] {aka swst}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, Eng (endoglin) [NCBI Gene 13805] {aka CD105, Endo, S-endoglin}, KLF2 (KLF transcription factor 2) [NCBI Gene 10365] {aka LKLF}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, ABCC2 (ATP binding cassette subfamily C member 2) [NCBI Gene 1244] {aka ABC30, CMOAT, DJS, MRP2, cMRP}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}
- **Diseases:** necrosis (MESH:D009336), liver decompensation (MESH:D017093), end-stage failure (MESH:D007676), cholestatic injury (MESH:D002779), dECM (MESH:C535509), acute liver failure (MESH:D017114), cytotoxicity (MESH:D064420), thrombosis (MESH:D013927), hypoxia (MESH:D000860), SCID (MESH:D053632), IALs (MESH:D060437), opportunistic infections (MESH:D009894), chronic kidney disease (MESH:D051436), hepatoblastoma (MESH:D018197), liver cirrhosis (MESH:D008103), fibrosis (MESH:D005355), injury to (MESH:D014947), inflammation (MESH:D007249), Chronic liver disease (MESH:D008107), cirrhotic (MESH:D000094724)
- **Chemicals:** alcohol (MESH:D000438), heparin (MESH:D006493), H (MESH:D006859), eosin (MESH:D004801), methacrylate (MESH:D008689), PES (MESH:C022840), glucose (MESH:D005947), poly-L-lactic acid (MESH:C033616), retrorsine (MESH:C003300), urea (MESH:D014508), polycaprolactone (MESH:C016240), H&amp;E (MESH:D006371), bile acids (MESH:D001647), genipin (MESH:C007834), Artificial (-), hematoxylin (MESH:D006416), Ba2+ (MESH:C080430), hyaluronic acid (MESH:D006820), E (MESH:D004540), phenol (MESH:D019800), glycogen (MESH:D006003), PEG (MESH:D011092), bilirubin (MESH:D001663), nickel (MESH:D009532), polymers (MESH:D011108), CCl4 (MESH:D002251), ammonia (MESH:D000641), Alginate (MESH:D000464), oxygen (MESH:D010100), chitosan (MESH:D048271)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823], Mus musculus (house mouse, species) [taxon 10090], Malus domestica (apple, species) [taxon 3750]
- **Cell lines:** HepaRG — Homo sapiens (Human), Hepatitis C infection, Cancer cell line (CVCL_9720), hy926 — Homo sapiens (Human), Hybrid cell line (CVCL_3901), C166 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_6581), C3A — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_1098), TMNK-1 — Homo sapiens (Human), Transformed cell line (CVCL_4W79), ELAD — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_8357), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), AML12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0140), LbL — Mus musculus (Mouse), Transformed cell line (CVCL_A1LI)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941630/full.md

---
Source: https://tomesphere.com/paper/PMC12941630